Interleukin-21 is a type I cytokine with actions on both lymphoid and myeloid cells. Soon after its discovery, IL-21 was shown to induce cytotoxic activity in both CD8+ T cells and NK cells, leading to the elucidation of its antitumor activity in animal models. This preclinical work led to the inclusion of IL-21 in human clinical trials in patients with advanced solid tumors, including melanoma and renal cell carcinoma. Encouraging results were seen with the use of IL-21 as a single agent, and it is possible that IL-21 might yield enhanced results as a component of combination therapy or in adoptive immunotherapy approaches for the generation of CD8+ T cells with potent antitumor activity.
KeywordsIL-21 Anti-tumor CD8+ T cells NK cells
R.S. and W.J.L. are supported by the Division of Intramural Research, National Heart, Lung, and Blood Institute, and National Institutes of Health.
Conflict of interest statement: R.S. and W.J.L. are inventors on patents and patent applications related to IL-21.
- Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, Mouritzen U, Hansen LT, Skak K, Lundsgaard D, Frederiksen KS, Kristjansen PE, McArthur G. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res. 2009;15:2123–9.CrossRefPubMedGoogle Scholar
- Frederiksen KS, Lundsgaard D, Freeman JA, Hughes SD, Holm TL, Skrumsager BK, Petri A, Hansen LT, McArthur GA, Davis ID, Skak K. IL‐21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother. 2008;57:1439–49.CrossRefPubMedPubMedCentralGoogle Scholar
- Kasaian MT, Whitters MJ, Carter LL, Lowe LD, Jussif JM, Deng B, Johnson KA, Witek JS, Senices M, Konz RF, Wurster AL, Donaldson DD, Collins M, Young DA, Grusby MJ. IL-21 limits NK cell responses and promotes antigen‐specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity. 2002;16:559–69.CrossRefPubMedGoogle Scholar
- Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, Qi CF, Hwu P, Shaffer DJ, Akilesh S, Roopenian DC, Morse 3rd HC, Lipsky PE, Leonard WJ. Regulation of B cell differentiation and plasma cell generation by IL‐21, a novel inducer of Blimp‐1 and Bcl‐6. J Immunol. 2004;173:5361–71.CrossRefPubMedGoogle Scholar
- Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, Schrader S, Burkhead S, Heipel M, Brandt C, Kuijper JL, Kramer J, Conklin D, Presnell SR, Berry J, Shiota F, Bort S, Hambly K, Mudri S, Clegg C, Moore M, Grant FJ, Lofton‐Day C, Gilbert T, Rayond F, Ching A, Yao L, Smith D, Webster P, Whitmore T, Maurer M, Kaushansky K, Holly RD, Foster D. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408:57–63.CrossRefPubMedGoogle Scholar
- Pot C, Jin H, Awasthi A, Liu SM, Lai CY, Madan R, Sharpe AH, Karp CL, Miaw SC, Ho IC, Kuchroo VK. Cutting edge: IL-27 induces the transcription factor c‐Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J Immunol. 2009;183:797–801.CrossRefPubMedPubMedCentralGoogle Scholar